In this video, we take a deep dive into IOL Chemicals & Pharmaceuticals Ltd, a smallcap pharma company that is a global leader in Ibuprofen APIs with ~30-35% market share.
Despite being debt-free and exporting to 80+ countries, the stock still trades at a discount valuation compared to peers.
In this research video we cover:
• Complete business model
• Key growth triggers
• Capacity expansion in Paracetamol & APIs
• Management strategy & diversification
• Financials and valuation comparison
• Risks that could turn it into an investment trap
• Multibagger potential over the next few years
The company is expanding non-Ibuprofen APIs like Paracetamol, Clopidogrel and Minoxidil, which could significantly drive revenue growth in the coming years.
If execution remains strong, the company could potentially scale revenue from ₹2,000 Cr to ₹5,000 Cr+ over the long term.
But there are also important risks investors must understand.
Watch the full analysis to understand whether this stock can truly become a long-term multibagger.
⚠️ Disclaimer
This video is for educational purposes only. Please do your own research before investing.